Thermo Scientific HR Multi-Attribute Method provides verified analytical workflow from development to manufacture of protein therapeutics
ATLANTA, June 3, 2019 /PRNewswire/ — ASMS 2019 – With the launch of a new high-resolution mass spectrometry-based workflow, biopharmaceutical scientists are no longer restricted by the complex series of assays typically required for the characterization and quality control of protein therapeutics.
The Thermo Scientific HR Multi-Attribute Method (MAM) meets the demand for a single, high-resolution mass spectrometry-based workflow designed to directly assess the product quality attributes of increasingly complex biotherapeutics. The workflow replaces the complicated sequence of lower-resolution methods that have previously prolonged characterization timelines. Supported by the Thermo Scientific Chromeleon Chromatography Data System (CDS) software, the HR MAM method simplifies and standardizes biotherapeutic characterization throughout the product pipeline, facilitating the transition of new drugs from initial research to development and manufacture.
Thermo Fisher Scientific is showcasing its new workflow during the 67th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 2–6, in the International Ballroom ABCD at the Omni CNN Center Hotel, Atlanta, Georgia.
Richard Rogers, PhD, Just Biotherapeutics, Inc., said, “Powerful Orbitrap technology and efficient search algorithms, like the one implemented in the BioPharma Finder software, allow us to fully leverage the HR MAM in the characterization of our biotherapeutics. One key component is new peak detection, which is essential for using MAM as a QC release method. The HR MAM contains all of the software components for characterizing and releasing biotherapeutics from QC.”
Additionally, companies including Amgen and Pfizer are testing and, in some cases, implementing MAM with Thermo Fisher Scientific products for their analytical processes.
“As a trusted partner of the biopharmaceutical industry, we appreciate that the ultimate goal of drug therapy development and manufacturing is to deliver the highest quality product at the lowest cost and in the shortest timeframe possible,” said Linda De Jesus, vice president and general manager, high performance chromatography solutions, Thermo Fisher Scientific. “With the launch and application of the HR MAM, the characterization and monitoring of biotherapeutics can be standardized across an organization – wherever their manufacturing operations are in the world – to ensure that each batch released is safe and of the highest quality.”
The HR MAM provides biopharmaceutical scientists with:
For more information on the Thermo Fisher solutions exhibited at ASMS 2019, please visit www.thermofisher.com/ASMS.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
Media Contact Information:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com
Ronan Muir
BioStrata
+44 (0) 1223 627133
rmuir@biostratamarketing.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/new-high-resolution-mass-spectrometry-based-workflow-simplifies-biopharmaceutical-characterization-and-quality-control-300860472.html
SOURCE Thermo Fisher Scientific
- Leading efficient care management for the elderly with unimpeded smartcare https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.png SEOUL, South Korea, Nov.…
- Attruby is the first and only approved product with aspecifying near-complete stabilization…
PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…